ARTERIAL THROMBOSIS VERSUS VENOUS THROMBOEMBOLISM
Traditional classifications have viewed arterial thrombosis and VTE as distinct pathological entities, with clear differentiating features. According to this classical schema, white thrombus characterizes the nascent arterial thrombosis, composed of an aggregate of platelets enmeshed in fibrin strands at the site of plaque rupture or erosion; while clot propagation (red thrombus) consists mostly of red blood cells entrapped in a growing fibrin network. Such propagation of the initial thrombus often occurs in cases of total arterial occlusion, such as in ST segment-elevation myocardial infarction (STEMI). Conversely, according to the classical view, venous thrombosis typically starts with the formation of a red thrombus, less dependent on platelets. Of the trio of precipitating factors postulated by Virchow, in VTE vessel wall injury traditionally lags in pathogenic relevance after hypercoagulability and stasis. Inherited thrombophilia, due to factor (F) V variants leading to resistance to activated protein C (APC) or the prothrombin variant G20210A, or the rarer natural anticoagulant antithrombin (AT) or protein C or protein S deficiencies, but also acquired thrombophilia in the setting of lupus anticoagulant or the anti-phospholipid antibody syndrome, increase the risk of VTE. Their link with arterial thrombosis (except in the case of the lupus anticoagulant) remains, however, unclear (17) (18) (19) .
This classical -totally dichotomous -view has recently come under scrutiny. Current concepts link the pathogenesis of arterial and venous thrombosis more tightly. Clinical evidence supports this reassessment: patients with arterial thrombosis have an increased risk of venous thrombotic events; a history of VTE associates with the risk of future arterial events; and the two conditions share several risk factors, including age, obesity, hypercholesterolemia, hypertension, lupus anticoagulant, hyperhomocysteinemia, microalbuminuria and non-alcoholic hepatosteatosis.
Moreover, evidence has emerged that platelets do indeed participate in venous thrombosis to a degree previously underestimated (20, 21) . This commonality has therapeutic implications: current studies support roles for aspirin, low-molecular weight heparin and warfarin in the treatment of both venous and arterial thrombosis (22-27). As a consequence, the silo thinking of VTE and arterial thrombosis as completely separate entities has given place to a new concept that includes VTE in a panvascular syndrome that comprises thrombotic complications affecting the veins as well as the coronary, peripheral, and cerebrovascular arterial beds (28) . The prevalence of carotid plaques in patients with unexplained venous thrombosis that exceeds that in those with events attributable to a well-identified cause (47.1% vs 27.4%), has stimulated consideration of a systemic thrombophilic state as an underlying feature (22). More recent evidence supports inflammation as a common 
RECIPROCAL RELATIONS BETWEEN INFLAMMATION AND THROMBOSIS
Inflammation and hemostasis can participate in a pathogenic positive feedback loop: inflammation unleashes hemostatic mechanisms, which in turn can amplify inflammation (29) (30) (31) . Both mechanisms participate in host defenses that help eliminate or contain pathogens, limit tissue damage, and -in order to resolve -evoke counter-regulatory mechanisms that tend to restore homeostasis. In particular, fibrin deposition can serve to wall-off invading agents and confine the consequent inflammatory response to a limited area, e.g., abscess formation in coagulase-positive S.
aureus infections (32) . An exaggerated or insufficiently controlled thrombotic response may however contribute to disease, such as in the case of the systemic activation occurring with severe infection or sepsis. This scenario results from a spatially uncontrolled systemic inflammatory response, and leads to multiple organ dysfunction and possibly failure in the setting of disseminated intravascular coagulation (32, 33) .
The interrelationship between inflammation and hemostasis reaches back to the early stages of evolution: invertebrates have a single cell type, the hemocyte, which can perform both antiinflammatory/immune and hemostatic functions. This overlap between innate immunity and hemostasis has endured over millions of years of evolution (34) . Cross talk between these the two functions involves cell receptor-mediated signaling, cell-cell interactions, and the production of cell-derived microvesicles, with dual functions, by endothelial cells, leukocytes and platelets (35) . Thus, therapeutic targeting of either coagulation or inflammation may influence the onset and the progression of multiple diseases the pathogenesis of which involves both processes (31, 32, 36) .
THROMBOSIS AS AN INFLAMMATORY PROCESS
Inflammation can perturb the hemostatic system, promoting a pro-thrombotic state, through several mechanisms (summarized in Table 1 and Figure 1 ): in particular, inflammation affects endothelial function, increases platelet reactivity, and activates plasma coagulation by activating procoagulant mechanisms and muting anticoagulant mediators (37) .
Endothelial cell dysfunction
Vascular endothelial cells furnish an antithrombotic surface that, in normal conditions, prevents the inappropriate activation of hemostasis through a balanced production of pro-and anti-inflammatory, pro-and anti-coagulant, anti-and pro-fibrinolytic molecules. Inflammation leads to an imbalance favoring procoagulant and antifibrinolytic components, including von Willebrand factor (VWF), thromboxane (TX)A 2 , plasminogen activator inhibitor (PAI)-1, TF, and cell adhesion molecules, causing a shift from an anticoagulant, anti-inflammatory and vasodilatory endothelial suite of functions to a proinflammatory and prothrombotic state. Endothelial cells contribute to inflammation-induced thrombosis acting at all levels of hemostasis, including the activation of platelets and other inflammatory cells, TF-mediated thrombin generation, reduction of physiologic anticoagulant functions, and the reduction/suppression of fibrinolytic activity. A number of small molecules also serve as pro-or anti-inflammatory mediators that may have impacts on thrombosis and hemostasis, including prostaglandins, reactive oxygen species, nitric oxide, and regulators of tissue remodeling enzymes (31) (Figure 1 ).
Platelet activation
Platelets not only participate in primary hemostasis, but also contribute to inflammation-induced thrombosis. Platelet activators include not only thrombin and ADP, but also molecules implicated in mediating inflammation, such as bacterial endotoxins (38) and the lipid mediator platelet-activating factor (PAF) (38). Activated platelets express on their surface or secrete pro-inflammatory and procoagulant substances, such as adhesion molecules, growth factors, cytokines (including Page 6 of 40  Thrombosis and Haemostasis   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 CD154/CD40 ligand) and the inhibitor of fibrinolysis PAI-1, and they allow the surface assembly of coagulation factors (39). Moreover, platelets contribute to a systemic prothrombotic state through the generation of TF-expressing MPs and the expression of P-selectin, which, through the activation of the transcription factor nuclear factor (NF)-κB, in turn promotes the production of proinflammatory molecules by endothelial cells and leukocytes, as well as the expression of TF in monocytes, endothelial and also smooth muscle cells (31, 32, 36, 40) .
Modulation of plasma coagulation
TF acts as the pivotal initiator of inflammation-induced thrombin generation, thus bridging inflammation and thrombosis (32) . Various cell types constitutively express this transmembrane molecule. Most TF-expressing cells localize in tissues that do not contact blood directly, such as in (6) . TF exposed to blood binds to FVIIa, which then catalyzes the conversion of FX into FXa directly or through the activation of FIX. FXa, FVa, prothrombin (FII) and calcium constitute key components of the prothrombinase complex on the surface of activated cells, able to generate thrombin, which then converts fibrinogen into fibrin (31, 32, 39, 44) . The main physiological anticoagulant mechanisms include antithrombin (AT), the protein C system and TF pathway inhibitor (TFPI). These mediators function to prevent blood clotting in physiological conditions and to limit coagulation activation to the site of vascular injury.
Impairment in their function represents an important mechanism of the procoagulant state associated with inflammation (31) . Antithrombin (AT, formerly AT III), a serine protease inhibitor, targets thrombin and FXa. AT levels decrease markedly in inflammation because of consumption (related to ongoing thrombin generation), impaired synthesis (as a result of the acute phase response), and degradation by neutrophil elastase (32) . Additionally, cytokines can reduce the synthesis of glycosaminoglycans on the endothelial surface, which otherwise normally promote the anticoagulant activity of AT (31) . The fibrinolytic system also modulates thrombosis induced by inflammation. Plasmin lyses clots by degrading fibrin. Generation of plasmin from plasminogen depends on the action of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Type-1 plasminogen activator inhibitor (PAI-1) can inhibit both of these plasminogen activators, reducing their fibrinolytic potential. Inflammatory states transiently increase fibrinolytic activity, due to the release of tPA stored in vascular endothelial cells, followed by a more sustained increase of endothelial PAI-1 production induced by TNF and IL-1. Moreover, platelets also contain preformed PAI-1 stored in alpha-granules, and release it upon their activation. Thus, inflammatory signaling yields a net inhibition of fibrinolysis, contributing to inflammation-induced thrombus accumulation (31, 32) .
Fibrinogen also participates in the inflammatory response. The liver synthesizes fibrinogen, an acute phase reactant the blood concentration of which increases in conditions characterized by infection or inflammation (44). Hyperfibrinogenemia not only serves as a biomarker of thrombotic risk, but can contribute causally to both venous and arterial thrombosis (45). An elevated plasma fibrinogen level (>4 mg/mL) associates significantly with increased risk of VTE in a concentrationdependent manner (45). Elevated fibrinogen levels increase blood viscosity and red blood cell agglutination in the setting of a hyperviscosity syndrome that increases blood flow shear stress, leading itself to endothelial cell and platelet activation (44). Moreover, several clinical studies have suggested that abnormal fibrin accumulation modulates thrombosis: clots with increased fibrin fiber density and resistance to fibrinolysis associate with both arterial and venous thrombosis (46-52).
The structure of the fibrin network reflects fibrinogen and thrombin concentration: indeed, elevated levels of fibrinogen and thrombin increase fibrin network density, clot stiffness, and the resistance of thrombi to fibrinolysis, contributing to clot accumulation and persistence (45).
Neutrophil extracellular traps: a novel link between innate immunity and thrombosis
Polymorphonuclear leukocytes participate pivotally in host defenses against infection or injury.
These neutrophilic leukocytes, attracted to sites of microbial invasion or tissue damage, release their granular contents, produce reactive oxygen species, generate lipid mediators, and then die, a process probably involving apoptosis. In the throes of death, neutrophils release strands of their nuclear DNA that become decorated with various proteins, among them the pro-oxidant enzyme myeloperoxidase, and the pro-coagulant tissue factor. These strands of extruded DNA provide a "solid state" reactor at sites of acute inflammation that can locally amplify oxidant stress and trigger thrombosis. Moreover, in combination with a fibrin network, these structures, known as neutrophil extracellular traps or NETs, participate in the propagation thrombosis, entrap platelets, and thus promote local thrombosis.
When NETs form on the intimal surface of veins or arteries, they can amplify and extend local thrombosis. Recent experimental work has documented that NETs provide a scaffold for thrombus formation, and participate in platelet activation (20) . Further observations implicated NETs in experimental (53) and in human venous thrombosis (54) . Markers of NET formation correlate with the severity of human coronary atherosclerosis and evidence for a prothrombotic state (13). In addition, NETs themselves can amplify inflammation by activating the NLRP3 inflammasome, a multimeric intracellular assembly of proteins that generates the active forms of the proinflammatory cytokines IL-1 beta and IL-18 (55) . Thus, NETs mediate a newly recognized mechanism that links innate immunity and inflammation. This pathway likely promotes the prolongation and propagation of local inflammatory and thrombotic responses in both veins and arteries (56) . The acute phase of two prototypic autoimmune skin diseases, chronic autoimmune urticaria and bullous pemphigoid, also associate with hypercoagulability, although only the latter condition has clearly increased thrombotic risk. The crosstalk between inflammation and thrombosis likely participates in the pathophysiology of both autoimmune diseases. The stronger activation of systemic coagulation in patients with bullous pemphigoid may contribute to the increased thrombotic risk. In these patients, the reduction in coagulation activation observed after immunosuppressive treatments may contribute to the healing of cutaneous manifestations, but also to the reduction of the associated thrombotic risk (65) .
Systemic inflammation can participate in the pathogenesis of the increased rates of thrombosis documented in other autoimmune diseases, such as autoimmune hemolytic anemia, immune thrombocytopenic purpura, systemic lupus erythematosus, systemic vasculitides, the antiphospholipid antibody syndrome, Sjögren's syndrome, and systemic sclerosis (66) (67) (68) (69) (70) .
Similarly, increased microvascular thrombosis is found in chronic and acute infections and in sepsis, where it contributes to multiple organ dysfunction. Indeed, strategies to manage microvascular thrombosis appear to reduce morbidity and mortality outcome in clinical studies (71, 72), illustrating the antithrombotic potential of aggressive anti-inflammatory treatment during the active phases of several types of diseases. The inflammatory aspects of atherosclerosis and its complications have already inspired several clinical trials aimed at testing the possibility that anti-inflammatory therapies will reduce cardiovascular events in various settings of risk, including trials with COX-2 inhibitors (coxibs), anti-TNF agents, etc. (5, 8, 73 ). Most such trials have either used agents not selective for targeting inflammation, or have lacked sufficient power to address cardiovascular endpoints.
ANTI-INFLAMMATORY THERAPIES IN CARDIOVASCULAR DISEASE
Statin treatment reduces the incidence of all-cause mortality and major coronary events in appropriately selected individuals in the setting of both secondary and primary prevention (74).
Statin therapy, beyond its effect on lipids, reduces the concentration of CRP (75), a biomarker that adds to prediction of risk of a first myocardial infarction and ischemic stroke in healthy men and women (76, 77) . Patients who achieve lower CRP levels on statin therapy have better clinical outcomes regardless of low-density lipoprotein (LDL) cholesterol levels (78) syndromes. The part A of the study followed over 3,500 patients, and the results did not support expanding of this preliminary part into a larger-scale outcome trial (81).
Two phase III studies (Table 3) A third ongoing phase IV trial of the effects of anti-inflammatory therapy on the incidence of 
CONCLUSIONS
Anti-inflammatory therapy to prevent atherothrombotic events, as in other therapeutic areas, may entail unwanted effects. The inflammatory and immune responses contribute importantly to host defenses. These pathways participate in combatting infections, in tumor surveillance, as well as in wound healing and tissue repair. Hence, the quest to identify anti-inflammatory therapies that will selectively inhibit effector arms of innate and adaptive immunity involved in atherothombosis without causing undue interruption of host defense mechanisms may require multiple attempts.
While rodent and other experiments can prove highly informative from the mechanistic viewpoint, they seldom predict accurately the full spectrum of efficacy or of adverse effects encountered in clinical trials (91) . Moreover, the high degree of redundancy in inflammatory signaling pathways presents a challenge, but also a potential advantage. A myriad of mediators (e.g., cytokines, chemokines, and lipid mediators) may promote the pathogenesis of the thrombotic complications of atherosclerosis. This menu provides a plethora of potential targets for intervention. From one perspective, this redundancy raises the hope that narrow blockade of a single mediator may provide Paul Ehrlich's hypothesized "magic bullet" to interrupt a pathogenic pathway, while the complementary mechanisms will limit undesired actions. Yet, the very multiplicity of mediators in host defenses indicates that the mere interruption of one of dozens of possible targets may not suffice to reduce events, as parallel pathways provide detours and bypasses should only one path be blocked. The survival value of host defenses has doubtless fostered this ability to compensate.
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LDL itself associates weakly with indices of information such as hsCRP. Yet, triglyceride-rich lipoproteins correlate strongly with this biomarker of inflammation (95). Thus, interventions that
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• Trials with statins have shown a previously unexpected reduction in venous thromboembolism, fueling the concept of "inflammationtriggered thrombosis"
What does this paper add?
• Here we review the multiple pathogenetic links between inflammation and thrombosis, and • Outline the ongoing trials with "pure" anti-inflammatory agents, now testing the hypothesis, all including venous thromboembolic episodes as endpoints. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
